3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Thrombocythemia, Essential
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Interventions
peginterferon alfa-2a
2
liposomal amphotericin B
2
anagrelide
2
Hydroxyurea
2
Early Intervention, Educational
2
Aspirin
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
peginterferon alfa-2b
1
bomedemstat
1
Pharmacogenomic Testing
1
Ondansetron
1
N(4)-oleylcytosine arabinoside
1
Morphine
1
Ketamine
1
Hypericum extract LI 160
1
Fentanyl
1
Dextromethorphan
1
Dalteparin
1
Caspofungin
1
Asian ginseng
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Thrombocythemia, Essential
×
bomedemstat
×
Clear all
NCT06351631
2026-04-02
MK-3543-017
Merck Sharp & Dohme LLC
Phase 3
Recruiting
400 enrolled